. 2018 Dec 4;13(12):e0208547. doi: 10.1371/journal.pone.0208547

Table 1. Baseline patient characteristics and overall survival in different groups.

		Colorectal cancer				Right-sided colorectal cancer				Left-sided colorectal cancer
Factors		Patient number	median survial	95% CI	P-value^a	Patient number	Median survival	95% CI	P-value^a	Patient number	Median survival	95% CI	P-value^a
Gender	Male	542	22.97	20.86–25.07	0.710	141	19.19	15.99–22.39	0.562	401	24.28	21.18–27.38	0.834
	Female	265	23.72	20.67–26.77		95	21.22	18.53–23.92		170	25.76	21.67–29.85
Age	< 65	617	24.00	21.53–26.47	0.036	179	20.7	18.47–22.93	0.226	438	26.48	23.77–29.19	0.083
	≥ 65	190	20.60	17.76–23.44		57	17.74	13.73–21.75		133	22.24	19.27–25.22
Lung metastasis	Only lung	73	32.85	26.77–38.94	0.001	17	40.97	19.02–62.92	0.037	56	32.62	25.35–39.90	0.015
	Non-pulmonary	734	22.24	20.67–23.81		219	19.19	16.65–21.72		515	23.75	21.41–26.10
Liver metastasis	Only liver	319	20.53	18.93–22.13	0.115	86	17.74	14.57–20.92	0.150	338	22.24	19.75–24.74	0.068
	Non-hepatic	488	25.59	23.11–28.08		150	21.19	17.40–24.98		233	27.66	24.55–30.77
Sidedness	Right	236	20.07	17.91–22.24	0.003
	Left	571	24.61	22.23–26.99
Pathological grade	Grade 1	34	30.55	3.53–57.58	0.058	9	30.55	1.20–59.91	0.132	25	20.07	1.81–38.34	0.238
	Grade 2	525	24.54	22.13–26.95	0.037^b	126	25.27	22.74–27.79	0.045^b	399	21.29	17.96–24.62	0.345^b
	Grade 3	248	19.52	17.41–21.62		101	21.52	17.81–25.33		147	17.74	14.63–20.86
Treatment	Chemotherapy	537	22.51	20.61–24.47	0.154	154	20.44	17.95–22.92	0.952	383	23.46	20.76–26.16	0.073
	Cetuximab	108	27.53	22.39–32.68	0.055^c	31	21.72	18.36–25.08	0.913^c	77	29.08	23.39–34.77	0.022^c
	Bevacizumab	162	23.72	18.74–28.70		51	17.02	14.41–19.63		111	28.12	22.67–33.57
NLR	≤ 3	508	28.09	25.51–30.67	<0.001	144	22.83	18.90–26.77	<0.001	364	29.5	26.71–32.30	<0.001
	> 3	299	18.23	15.93–20.54		92	13.41	11.43–15.38		207	19.65	17.35–21.97
PLR	≤ 169	438	26.65	23.88–29.41	<0.001	107	22.97	19.95–25.98	0.007	331	28.52	25.61–31.43	<0.001
	> 169	369	19.25	17.52–20.99		129	16.56	13.93–19.18		240	20.53	17.86–23.21
CEA	≤ 5 ng/mL	227	28.95	24.01–33.88	<0.001	66	25.59	17.63–33.56	0.003	161	30.16	24.96–35.36	0.001
	> 5 ng/mL	580	21.22	19.60–22.85		170	19.19	16.47–21.90		410	22.5	20.16–24.84
CA19-9	≤ 37 U/mL	408	29.31	26.08–32.53	<0.001	110	27.43	21.20–33.66	<0.001	298	31.24	27.57–34.92	<0.001
	> 37 U/mL	399	19.29	17.68–20.89		126	15.67	12.38–18.96		273	20.53	18.57–22.50
LDH	≤ 250 U/L	573	28.91	26.32–31.50	<0.001	174	21.72	18.09–25.35	<0.001	399	30.55	27.83–33.28	<0.001
	> 250 U/L	234	14.98	13.38–16.59		62	12.58	9.91–15.25		172	15.93	14.23–17.63
CRP	≤ 3 mg/L	319	29.01	26.10–31.92	<0.001	84	27.43	23.69–31.18	<0.001	235	30.16	26.33–34.00	<0.001
	> 3 mg/L	488	19.55	18.00–21.10		152	15.93	12.38–19.49		336	21.22	19.07–23.38

^a P-values were calculated using the Kaplan–Meier method with log-rank test.

^b P-value between grade 1–2 differentiation and grade 3 differentiation regarding OS.

^c P-value between target therapy (bevacizumab and cetuximab) plus chemotherapy and chemotherapy regarding OS.

NLR, the neutrophil-to-lymphocyte ratio; PLR, the platelet-lymphocyte ratio; CEA, carcinoembryonic antigen; CA 19–9, carbohydrate antigen 19–9; LDH, lactate dehydrogenase; CRP, C-reactive protein; 95% CI, 95% confidence interval.